SLNSW-Gefitinib plus chemotherapy versus placebo plus c...-TN_cdi_proquest_journals_1702711084

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Full title: Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Author/creator: Soria, Jean-Charles, Prof, Wu, Yi-Long, Prof, Nakagawa, Kazuhiko, Prof, Kim, Sang-We, Prof, Yang, Jin-Ji, MD, Ahn, Myung-Ju, Prof, Wang, Jie, MD, Yang, James Chih-Hsin, Prof, Lu, You, Prof, Atagi, Shinji, MD, Ponce, Santiago, MD, Lee, Dae Ho, Prof, Liu, Yunpeng, Prof, Yoh, Kiyotaka, MD, Zhou, Jian-Ying, Prof, Shi, Xiaojin, MD, Webster, Alan, MSc, Jiang, Haiyi, MD, Mok, Tony S K, Prof.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_1702711084

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1702711084

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

    Record identifier

    TN_cdi_proquest_journals_1702711084

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1702711084

    Share

    Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1702711084

    Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

    Full title

    Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR -mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

    Author / Creator

    Soria, Jean-Charles, Prof ; Wu, Yi-Long, Prof ; Nakagawa, Kazuhiko, Prof ; Kim, Sang-We, Prof ; Yang, Jin-Ji, MD ; Ahn, Myung-Ju, Prof ; Wang, Jie, MD ; Yang, James Chih-Hsin, Prof ; Lu, You, Prof ; Atagi, Shinji, MD ; Ponce, Santiago, MD ; Lee, Dae Ho, Prof ; Liu, Yunpeng, Prof ; Yoh, Kiyotaka, MD ; Zhou, Jian-Ying, Prof ; Shi, Xiaojin, MD ; Webster, Alan, MSc ; Jiang, Haiyi, MD ; Mok, Tony S K, Prof

    Publisher

    England: Elsevier Ltd

    Journal title

    The lancet oncology, 2015, Vol.16 (8), p.990-998

    Record Identifier

    TN_cdi_proquest_journals_1702711084

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Administration, Oral Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Asia Biomarkers, Tumor - genetics Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - enzymology Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Chemotherapy Cisplatin - administration & dosage Clinical medicine Disease Progression Disease-Free Survival Drug Administration Schedule Europe Female Gefitinib Genetic aspects Genetic Predisposition to Disease Glutamates - administration & dosage Guanine - administration & dosage Guanine - analogs & derivatives Hematology, Oncology and Palliative Medicine Humans Infusions, Intravenous Kaplan-Meier Estimate Kinases Lung cancer Lung cancer, Non-small cell Lung diseases Lung Neoplasms - drug therapy Lung Neoplasms - enzymology Lung Neoplasms - genetics Lung Neoplasms - mortality Lung Neoplasms - pathology Male Medical colleges Middle Aged Mutation Pemetrexed Phenotype Product development Proportional Hazards Models Prospective Studies Protein Kinase Inhibitors - administration & dosage Quinazolines - administration & dosage Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - genetics Receptor, Epidermal Growth Factor - metabolism Strategic planning (Business) Time Factors Treatment Outcome Tumors

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_1702711084

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1702711084

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections